Amgen AMGN
Price chart
Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
Community Sentiment on AMGN
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Strategy Backtest
Pick a strategy above and run the backtest to see its simulated performance on AMGN.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
AMGN at a glance
Shares of Amgen are up 0.03% at $460.42. The company is worth $249.05B, number 68 out of 3753 on our list.
Over the past 52 weeks it has traded between $306.12 and $483.99, so it sits 4.9% below the top of that range. Holders are ahead 47.8% over twelve months, and up 11.0% across the last three months.
On the chart it holds above both the 50-day ($422.43) and 200-day ($375.27) moving averages; RSI is 60, and the last 30 sessions moved at roughly 29% annualized volatility.
In the quarter ended Jun 2026 the company brought in $10.05B of revenue, up 9.5% from a year earlier, with $2.38B of net profit (a 23.0% margin).
The stock changes hands at 26.7 times trailing earnings, about in line with its own five-year average of 26.7. The median for its industry group is 17.8.
19 analysts follow the stock and the average call is "buy". The mean target, $462.88, sits 0.5% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
BeStock Grade
Composite of 4 factors below, ranked against the 3741 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Higher trailing yield than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
19 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
BeStock Momentum
AMGN is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-12-28, the strategy has returned 437.6% (203.8% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.
Price forecast
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $462.88, 0.5% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $342.00, so shares trade 34.6% above that estimate. On earnings multiple, it sits in the 80th percentile of its own five-year valuation range (pricier than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Amgen: the business
Amgen is a biotech company with established drugs in bone health, inflammation, cardiovascular disease and oncology, plus a growing biosimilars business.
What tends to move it. Patent expirations on older drugs, the rollout of its obesity candidate and pricing pressure from Medicare shape the outlook.
Where the case gets weaker. Older drugs losing patent protection creates a revenue hole that has to be filled by newer products, and a weak or delayed launch of its obesity drug would leave that gap only partly covered while Medicare pricing pressure keeps squeezing margins.
Written by hand by the BeStock desk and revised when a business changes. how we work. Spot something out of date? Tell us.
Performance
Price return over each window, from adjusted daily and weekly closes
Technical signals
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +3.4% | Bullish |
| Price vs 50-day average | +9.0% | Bullish |
| Price vs 200-day average | +22.7% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 60.5 | Bullish |
| MACD (12,26,9) | 13.56 | Bullish |
| Bollinger band position | 71% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Key statistics
Quote as of Nov 6, 2026 9:50 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
How AMGN ranks on BeStock
Ranks are among the 3,741 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 26.7x earnings, AMGN looks expensive against the market, and trades 50% above the 17.8x median among Drug Manufacturers - General names. The two comparisons do not always agree.
AMGN stock: common questions
How is Amgen stock doing today?
$460.42 is the latest print for AMGN, a move of +0.03% against yesterday's close of $460.28. Today's low and high so far: $447.04 and $462.91.
How large is Amgen by market value?
Equity value comes to $249.05B at the current price. By that measure it is number 68 of the 3753 names in our coverage.
What multiple of earnings does AMGN sell for?
Buyers pay 26.7 times the last twelve months of profit (EPS $14.23). Averaged over five years the multiple has been 26.7, and today's level ranks in the 80th percentile of its own history.
What's the 52-week trading range for Amgen?
The year's floor is $306.12 and the ceiling $483.99. Shares are 4.9% away from that ceiling.
What's the dividend situation for AMGN?
It does. Payouts over the past twelve months work out to a 2.16% yield; the latest ex-dividend date was August 21, 2026.
What are analysts saying about AMGN?
Of 19 analysts, 47% say buy, 47% hold and 5% sell. Price targets average $462.88, with the most cautious at $347.00 and the most optimistic at $536.00.
In plain terms, what does Amgen sell?
Amgen is a biotech company with established drugs in bone health, inflammation, cardiovascular disease and oncology, plus a growing biosimilars business.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on AMGN.
Sign in to join the discussion.